Literature DB >> 26321065

Surgical treatment of bisphosphonate-associated osteonecrosis: Prognostic score and long-term results.

Waldemar Reich1, Udo Bilkenroth2, Johannes Schubert3, Claudia Wickenhauser4, Alexander Walter Eckert5.   

Abstract

Over a century after the first synthesis of bisphosphonates (1897) and a decade (2003) since the initial report on bisphosphonate-related osteonecrosis of the jaw (ONJ), this osteopathy remains a serious clinical challenge. A single center longitudinal study (2005-2014) was carried out to prospectively characterize inpatients with manifest ONJ and to evaluate their outcomes. The data recorded were: medical history, bisphosphonate treatment, localization, imaging, treatment, histomorphological features, and complications. A prognostic score (modified UCONN-Score) was adopted to predict outcomes. Eighty patients were included (mean age 69.4 years; 40 male, 40 female). Breast cancer (n = 25), multiple myeloma (n = 16), and prostate cancer (n = 15) were the three most common malignancies; and cardiovascular disease (n = 31), diabetes mellitus (16), and renal disorders (6) were the most important comorbidities. The severity of ONJ was stage I in three patients, stage II in 37, and stage III in 40, being predominantly localized in the posterior mandible and needing gradual resection. The average duration of bisphosphonate treatment was 38.3 months. The typical histological aspects of ONJ were predominantly osteonecrosis, bone marrow fibrosis, and bacterial colonization (Actinomyces) with suppurative inflammation. Within the resected jawbone a primary malignancy was diagnosed in two cases. The overall success rate was 83.6% (follow-up 23.5 months), with a UCONN-Score ≥15 predicting unfavorable treatment results (OR = 5.2). The past decade has enhanced experience with ONJ treatment and knowledge about its pathogenesis, which seems to be a multistep process. This study demonstrates the importance of bone and multilayer soft tissue management, preferably as an early intervention. The UCONN-Score might help to assess individual prognosis in ONJ surgery and the potential benefit of an antiresorptive drug holiday. To our knowledge it is the first use of a prognostic score in ONJ surgery.
Copyright © 2015 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bisphosphonate; Histopathology; Osteonecrosis; Outcome; Radiology; Score

Mesh:

Year:  2015        PMID: 26321065     DOI: 10.1016/j.jcms.2015.07.035

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  12 in total

1.  Influence of the cumulative effect of zoledronic acid on periodontal microcirculation in rats.

Authors:  G A Kosach; A L Petrosyan; A I Yaremenko; S I Kutukova; A A Zubareva; S G Chefu; T D Vlasov
Journal:  Oral Maxillofac Surg       Date:  2021-02-14

Review 2.  Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: Systematic review and meta-analysis.

Authors:  Mohamed E Awad; Christina Sun; Joshua Jernigan; Mohammed Elsalanty
Journal:  J Am Dent Assoc       Date:  2019-06-28       Impact factor: 3.634

3.  Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol.

Authors:  Luca Ramaglia; Agostino Guida; Vincenzo Iorio-Siciliano; Alessandro Cuozzo; Andrea Blasi; Anton Sculean
Journal:  Clin Oral Investig       Date:  2018-01-13       Impact factor: 3.573

4.  Submental Perforator Flap for Soft-Tissue Reconstruction in Bisphosphonate-Related Osteonecrosis of the Jaws.

Authors:  Jose-Antonio García-de Marcos; Juan Rey-Biel
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2016-11-01

5.  Nonsurgical Management of Medication-Related Osteonecrosis of the Jaws Using Local Wound Care.

Authors:  Danny Hadaya; Akrivoula Soundia; Earl Freymiller; Tristan Grogan; David Elashoff; Sotirios Tetradis; Tara L Aghaloo
Journal:  J Oral Maxillofac Surg       Date:  2018-05-29       Impact factor: 1.895

6.  Evaluation of the predisposing factors and involved outcome of surgical treatment in bisphosphonate-related osteonecrosis of the jaw cases including bone biopsies.

Authors:  Tae-Hwan Kim; Won-Gyo Seo; Chul-Hong Koo; Jae-Hoon Lee
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2016-08-24

7.  Treatment of bisphosphonate-related osteonecrosis of the jaws - a report of seven cases.

Authors:  Joanna Jakiel; Mansur Rahnama; Joanna Szczerba-Gwóźdź
Journal:  Contemp Oncol (Pozn)       Date:  2017-01-12

8.  Histomorphometric Effects of 2% Risedronate Gel on Calvarial Bone Defects in Rabbits.

Authors:  Shabnam Aghayan; Ahmad Asghari; Pejman Mortazavi; Shirin Marzoughi
Journal:  J Dent (Shiraz)       Date:  2021-03

9.  Characteristics of patients with osteonecrosis of the jaw with oral versus intravenous bisphosphonate treatment.

Authors:  Seung-Hun Lee; So-Young Choi; Min-Su Bae; Tae-Geon Kwon
Journal:  Maxillofac Plast Reconstr Surg       Date:  2021-07-08

10.  Prognostic factors for outcome of surgical treatment in medication-related osteonecrosis of the jaw.

Authors:  Woo Jin Shin; Chul-Hwan Kim
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2018-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.